AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 16398842
Drug: Calcium and
RxNorm normalized name: Calcium and Magnesium
DrugBank: Calcium carbonate (DB06724)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Calcium and vitamin D supplementation combined with bisphosphonate treatment (non-trial patients, n = 11)
Trial: 12472324
Drug: rHuEPO (40,000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rHuEPO (40,000 units administered weekly by subcutaneous injection)
Trial: 2236459
Drug: Enciprazine (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enciprazine (5 mg t.i.d., 10 mg t.i.d., and 20 mg t.i.d.)
Trial: 16889458
Drug: Cognitive-behavioral group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive-behavioral group therapy (CBGT) for 12 weeks
Trial: 15605617
Drug: Sertraline 100
RxNorm normalized name: sertraline 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sertraline 100 mg/day for 12 weeks
Trial: 15171752
Drug: Troglitazone followed
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Troglitazone followed by rosiglitazone (4 mg/day) or pioglitazone (30 mg/day)
Trial: 15171752
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no antidiabetic medication)
Trial: 11566518
Drug: Topical anesthesia
RxNorm normalized name: Gelato Anesthetic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical anesthesia (oxybuprocaine 0.4%)
Trial: 11566518
Drug: Combined anesthesia
RxNorm normalized name: Gelato Anesthetic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined anesthesia (topical anesthesia and propofol sedation)
Trial: 9054252
Drug: Dexmedetomidine infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexmedetomidine infusion (50 ng.kg-1.min-1 for 30 min before induction, then 7 ng.kg-1.min-1 until end of surgery)
Trial: 3608513
Drug: Homologous human
RxNorm normalized name: Insulin Human
DrugBank: Insulin human (DB00030)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Homologous human fibronectin (300 micrograms/ml), mixed with gentamicin and artificial tears, 4 times a day
Trial: 24021497
Drug: Lisdexamfetamine dimesylate
RxNorm normalized name: Lisdexamfetamine Dimesylate
DrugBank: Lisdexamfetamine (DB01255)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Lisdexamfetamine dimesylate (20-50 mg/d)
Trial: 21917907
Drug: Leptin administration
RxNorm normalized name: leptin
DrugBank: Leptin (DB05098)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Leptin administration (twice daily injections)
Trial: 21917907
Drug: Placebo administration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo administration (twice daily injections)
Trial: 17557312
Drug: Doxapram (respiratory
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Doxapram (respiratory stimulant), dosage and duration not specified
Trial: 17007369
Drug: Mizolastine (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mizolastine (10 mg once daily for 3 weeks)
Trial: 17007369
Drug: Cetirizine (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cetirizine (10 mg once daily for 3 weeks)
Trial: 12781882
Drug: Neoadjuvant chemoradiation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neoadjuvant chemoradiation and surgery (concurrent)
Trial: 12781882
Drug: Neoadjuvant chemoradiation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neoadjuvant chemoradiation and surgery (sequential)
Trial: 12413260
Drug: Technique G
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Technique G (IVECG signal from guide wire)
Trial: 12413260
Drug: Technique G
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Technique G
Trial: 9669144
Drug: Combined therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined therapy with calcium and vitamin D
Trial: 31831363
Drug: DHA-rich fish
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DHA-rich fish oil (2400 mg/d) for 8 weeks
Trial: 31593702
Drug: Dupilumab (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dupilumab (300 mg weekly subcutaneous injections)
Trial: 20976617
Drug: 16-week Theory
RxNorm normalized name: lacosamide
DrugBank: Lacosamide (DB06218)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 16-week Theory of Mind (ToM) treatment
Trial: 19135798
Drug: Remifentanil (two
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Remifentanil (two different clinically relevant doses)
Trial: 17303791
Drug: Chromium treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chromium treatment (400 microg of chromium daily in the form of chromium yeast)
Trial: 15519185
Drug: methylprednisolone, 5
RxNorm normalized name: MethylPREDNISolone, 500 mg injectable powder for injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: methylprednisolone, 5 mg/kg body weight
Trial: 15519185
Drug: methylprednisolone, 10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: methylprednisolone, 10 mg/kg body weight
Trial: 7931889
Drug: Intranasal fluticasone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intranasal fluticasone propionate, 200 micrograms once daily for 4 weeks
Trial: 7931889
Drug: Intranasal fluticasone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intranasal fluticasone propionate, 100 micrograms once daily for 4 weeks
Trial: 8092559
Drug: Intranasal fluticasone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intranasal fluticasone propionate (both dosages)
Trial: 3076051
Drug: Sodium fluoride
RxNorm normalized name: Sodium Fluoride
DrugBank: Sodium fluoride (DB09325)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sodium fluoride therapy (pure sodium fluoride powder, Ossin, Koreberon)
Trial: 3076051
Drug: Sodium fluoride
RxNorm normalized name: Sodium Fluoride
DrugBank: Sodium fluoride (DB09325)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sodium fluoride therapy (Koreberon)
Trial: 25415292
Drug: 4-drug regimen
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 4-drug regimen vs 3-drug arm
Trial: 23922746
Drug: L-arginine (12
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-arginine (12 g over 8 hours)
Trial: 20671070
Drug: 3 months
RxNorm normalized name: TABLET, DOSE PACK, 3 MONTHS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 months post-treatment (T3)
Trial: 19439881
Drug: 1% clindamycin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1% clindamycin lotion (C lotion) twice daily
Trial: 19439881
Drug: 1% clindamycin+0.025%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1% clindamycin+0.025% tretinoin lotion once nightly (CT lotion)
Trial: 19439881
Drug: 1% clindamycin+2%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1% clindamycin+2% salicylic acid lotion twice daily (CS lotion)
Trial: 19439881
Drug: Comparison of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Comparison of all treatments
Trial: 15656050
Drug: Behavioral therapy
RxNorm normalized name: RelieVRx Virtual Reality Behavioral Therapy for Pain Relief
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Behavioral therapy (weight loss and positional therapy)
Trial: 15656050
Drug: CPAP (standard
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CPAP (standard therapy)
Trial: 11379377
Drug: Continuous combined
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous combined HRT (conjugated equine estrogen 0.625 mg plus medroxyprogesterone acetate 5 mg)
Trial: 11379377
Drug: Low-dose oral
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose oral estrogen (estriol 2 mg daily)
Trial: 11379377
Drug: Unopposed transdermal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Unopposed transdermal estrogen (estradiol 50 micrograms/24 h)
Trial: 3683485
Drug: Continuous chemotherapy
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous chemotherapy (doxorubicin combined with cyclophosphamide or cyclophosphamide combined with methotrexate, fluorouracil, and prednisone)
Trial: 3683485
Drug: Intermittent chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intermittent chemotherapy (stopped after three cycles, repeated only with disease progression)
Trial: 29258028
Drug: CBT4CBT (computer-based
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CBT4CBT (computer-based Cognitive Behavioral Therapy)
Trial: 23852077
Drug: Transdermal diclofenac
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transdermal diclofenac patches
Trial: 23294179
Drug: Combination regimen
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination regimen of glucosamine and low-dose cyclosporin A (C)
Trial: 23294179
Drug: Single regimen
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single regimen of low-dose cyclosporin A (S)
Trial: 17096678
Drug: Triptorelin (3.75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Triptorelin (3.75 mg, single subcutaneous or intramuscular injection)
Trial: 17096678
Drug: Degarelix (120-320
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Degarelix (120-320 mg, multiple subcutaneous doses)
Trial: 15366325
Drug: Deramciclane 60
RxNorm normalized name: Deramciclane
DrugBank: Deramciclane (DB06512)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Deramciclane 60 mg b.i.d. for 4 weeks
Trial: 11535548
Drug: 60 mg/day
RxNorm normalized name: cabozantinib s-malate 60 mg/day (20 mg x 3/day) ORAL CAPSULE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 60 mg/day raloxifene
Trial: 11451623
Drug: 120 mg/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 120 mg/day raloxifene
Trial: 11451623
Drug: Hormone replacement
RxNorm normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Hormone replacement therapy (0.625 mg/day conjugated equine estrogen and 2.5 mg/day medroxyprogesterone acetate)
Trial: 8052956
Drug: Conjugated estrogens
RxNorm normalized name: Conjugated Estrogens
DrugBank: Conjugated estrogens (DB00286)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Conjugated estrogens (CE) 0.625 mg
Trial: 8052956
Drug: Transdermal estradiol
RxNorm normalized name: estradiol Transdermal System
DrugBank: Estradiol (DB00783)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Transdermal estradiol (E2) 50 micrograms/24h
Trial: 30078280
Drug: Hydromorphone (0.01
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydromorphone (0.01 mg/kg)
Trial: 27082036
Drug: Multi-component influenza
RxNorm normalized name: Parasedge Multi
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multi-component influenza and Tdap vaccine promotion package
Trial: 14675952
Drug: Surgical access
RxNorm normalized name: ACCESS PIN
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Surgical access therapy
Trial: 14675952
Drug: Systemic administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Systemic administration of metronidazole as an adjunct to mechanical treatment
Trial: 14675952
Drug: Mechanical treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mechanical treatment
Trial: 10527711
Drug: 7 ml
RxNorm normalized name: ethanol 7 ML/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 7 ml liquid cartilage extract
Trial: 10527711
Drug: 21 ml
RxNorm normalized name: ethanol 0.21 ML/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 21 ml liquid cartilage extract
Trial: 1677063
Drug: Cyclosporin (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cyclosporin (5 mg/kg per day)
Trial: 6223289
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of 200 micrograms fenoterol hydrobromide and 80 micrograms ipratropium bromide
Trial: 26787637
Drug: Manually Controlled
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Manually Controlled Infusion (MCI)
Trial: 24817188
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of continuous and intermittent theta-burst stimulation (Group C)
Trial: 23010558
Drug: AZD6370 20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AZD6370 20 mg
Trial: 23010558
Drug: AZD6370 60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AZD6370 60 mg
Trial: 23010558
Drug: AZD6370 180
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AZD6370 180 mg
Trial: 23010558
Drug: AZD6370 (180
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AZD6370 (180 mg total dose in one, two or four divided doses)
Trial: 19281330
Drug: 2 doses
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 doses of 15 microg of inactivated, aluminum-adjuvanted, whole-virion H5N1 vaccine
Trial: 19281330
Drug: 2 doses
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 doses of 10 microg of inactivated, aluminum-adjuvanted, whole-virion H5N1 vaccine
Trial: 19281330
Drug: 2 doses
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 doses of 10 microg of inactivated, aluminum-adjuvanted, whole-virion H5N1 vaccine (14 days apart)
Trial: 10450538
Drug: 300 mg
RxNorm normalized name: rutin 300 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 300 mg dihydroartemisinin
Trial: 10450538
Drug: 300 mg
RxNorm normalized name: rutin 300 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 300 mg dihydroartemisinin with 750 mg mefloquine
Trial: 7761739
Drug: Caffeine (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Caffeine (2 mg/kg) added to decaffeinated coffee at 2220 and 0120 hours for the first 3 nights.
Trial: 2143266
Drug: Loratadine (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Loratadine (5 mg daily; 2.5 mg for children under 20 kg)
Trial: 2143266
Drug: Dexchlorpheniramine (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexchlorpheniramine (1 mg every 8 hours; 0.5 mg for the youngest children)
Trial: 2143266
Drug: Overall clinical
RxNorm normalized name: DuoCare Clinical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Overall clinical assessment for both drugs
Trial: 31999300
Drug: Ranibizumab (0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ranibizumab (0.5 mg intravitreous injections)
Trial: 31999300
Drug: Ranibizumab (after
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ranibizumab (after censoring VF results after PRP treatments)
Trial: 31999300
Drug: Laser treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Laser treatment (initial PRP session)
Trial: 31999300
Drug: Laser treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Laser treatment (additional PRP sessions)
Trial: 31999300
Drug: Laser treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Laser treatment (endolaser)
Trial: 30172451
Drug: Mirabegron 25
RxNorm normalized name: mirabegron 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mirabegron 25 mg daily for 12 weeks
Trial: 30172451
Drug: Mirabegron 25
RxNorm normalized name: mirabegron 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mirabegron 25 mg daily for 4 weeks + 50 mg daily for 8 weeks
Trial: 30172451
Drug: Mirabegron 25
RxNorm normalized name: mirabegron 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mirabegron 25 mg for 4 weeks followed by 50 mg for 8 weeks
Trial: 18466654
Drug: Low GI
RxNorm normalized name: Yellow Ginger Root
DrugBank: Turmeric (DB14276)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low GI and low GL (L-L)
Trial: 18466654
Drug: High GI
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High GI and low GL (H-L)
Trial: 10998876
Drug: PCEA using
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PCEA using a disposable PCA device (3.0 ml type)
Trial: 10998876
Drug: Continuous epidural
RxNorm normalized name: ACCU-BLOC PERIFIX CONTINUOUS EPIDURAL ANESTHESIA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous epidural group with epidural fentanyl (15 micrograms.ml‐1) and bupivacaine (1.25 mg.ml‐1)
Trial: 8698952
Drug: 8-session cognitive-behavioral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 8-session cognitive-behavioral therapy (CB)
Trial: 8698952
Drug: 16-session cognitive-behavioral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 16-session cognitive-behavioral therapy (CB)
Trial: 8698952
Drug: 8-session psychodynamic-interpersonal
RxNorm normalized name: AVOBENZONE 30 mg in 1 mL / HOMOSALATE 100 mg in 1 mL / OCTISALATE 50 mg in 1 mL / OCTOCRYLENE 60 mg in 1 mL TOPICAL LOTION [SESSION SAVERS SUNSCREEN BROAD SPECTRUM SPF 30 WATER RESISTANT]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 8-session psychodynamic-interpersonal therapy (PI)
Trial: 8698952
Drug: 16-session psychodynamic-interpersonal
RxNorm normalized name: AVOBENZONE 30 mg in 1 mL / HOMOSALATE 100 mg in 1 mL / OCTISALATE 50 mg in 1 mL / OCTOCRYLENE 60 mg in 1 mL TOPICAL LOTION [SESSION SAVERS SUNSCREEN BROAD SPECTRUM SPF 30 WATER RESISTANT]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 16-session psychodynamic-interpersonal therapy (PI)
Trial: 8698952
Drug: psychodynamic-interpersonal therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: psychodynamic-interpersonal therapy (PI)
Trial: 8698952
Drug: cognitive-behavioral therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: cognitive-behavioral therapy (CB)
Trial: 8698952
Drug: 8-session treatments
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 8-session treatments
Trial: 8698952
Drug: 16-session treatments
RxNorm normalized name: benzoyl peroxide
DrugBank: Benzoyl peroxide (DB09096)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 16-session treatments
Trial: 22155435
Drug: Beta-blocker (BB)
RxNorm normalized name: Beta Carotene
DrugBank: Beta carotene (DB06755)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Beta-blocker (BB) up-titration
Trial: 20422396
Drug: Antidepressant medicines
RxNorm normalized name: Percy Medicine
DrugBank: Bismuth subsalicylate (DB01294)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Antidepressant medicines (ADMs) use
Trial: 16940738
Drug: Oral misoprostol
RxNorm normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral misoprostol 400 mug
Trial: 15491319
Drug: Control protocol:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control protocol: rinsed twice daily for 1 min with 0.1% chlorhexidine (CHX) for 4 weeks.
Trial: 15491319
Drug: Test protocol:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Test protocol: applied CHX locally using a very soft surgical toothbrush from days 3 to 14, and a soft toothbrush from days 14 to 28, twice daily, in addition to CHX rinsing.
Trial: 14655831
Drug: Citalopram at
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Citalopram at a starting dose of 20 mg for 6 months
Trial: 8306595
Drug: Self-titrating insulin
RxNorm normalized name: insulin, regular, human
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Self-titrating insulin regimen
Trial: 8306595
Drug: Pre-mixed insulin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pre-mixed insulin (30:70) delivered by disposable pen
Trial: 8306595
Drug: Insulin ratios
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Insulin ratios other than 30:70
Trial: 8306595
Drug: Preference for
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Preference for disposable pen and pre-mixed insulin regimen
Trial: 30589994
Drug: ACT-774312 50
RxNorm normalized name: ACT-541468
DrugBank: Daridorexant (DB15031)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: ACT-774312 50 mg twice daily
Trial: 30589994
Drug: ACT-774312 (single
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ACT-774312 (single doses of 1-1000 mg or multiple doses of 30-500 mg)
Trial: 29522079
Drug: Treatment-as-prevention intervention
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment-as-prevention intervention including monthly testing for HIV and rapid treatment initiation for those who became HIV-positive.
Trial: 29522079
Drug: Monthly testing
RxNorm normalized name: mumps skin test antigen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Monthly testing for HIV among HIV-negative individuals.
Trial: 26794930
Drug: Everolimus (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Everolimus (10 mg/day)
Trial: 26794930
Drug: Sunitinib (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sunitinib (50 mg/day; 6-week cycles of 4 weeks on, 2 weeks off)
Trial: 24178792
Drug: Anatabine (9-24
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anatabine (9-24 mg/d), administered orally 3 times a day for 3 months
Trial: 24178792
Drug: Placebo, administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo, administered orally 3 times a day for 3 months
Trial: 17487260
Drug: Carvedilol in
RxNorm normalized name: Product containing carvedilol in oral dose form (medicinal product form)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Carvedilol in addition to ACE inhibitor
Trial: 17487260
Drug: ACE inhibitor
RxNorm normalized name: ACE INHIBITORS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ACE inhibitor without any beta-blocker (control)
Trial: 9654256
Drug: Interferon alpha‐2a
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Interferon alpha‐2a (3x10(6) IU, three times weekly for 18 months)
Trial: 8270984
Drug: 20-mg tamoxifen
RxNorm normalized name: tamoxifen 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20-mg tamoxifen tablet taken once daily
Trial: 8270984
Drug: 10-mg tamoxifen
RxNorm normalized name: tamoxifen 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10-mg tamoxifen tablet taken twice daily